@Article{ecn.2013.0342,
AUTHOR = {Benjamin Piura, Liat Medina, Alex Rabinovich, Victor Dyomin, Mahmoud Huleihel},
TITLE = {Thalidomide distinctly affected TNF-α, IL-6 and MMP secretion by an ovarian cancer cell line (SKOV-3) and primary ovarian cancer cells},
JOURNAL = {European Cytokine Network},
VOLUME = {24},
YEAR = {2013},
NUMBER = {3},
PAGES = {122--129},
URL = {http://www.techscience.com/ECN/v24n3/65630},
ISSN = {1952-4005},
ABSTRACT = {Background. Thalidomide inhibits TNF-α production in lipopolysaccharide-stimulated monocytes.
The aim of this study was to evaluate the effect of thalidomide on TNF-α, IL-6 and MMP secretion in epithelial
ovarian carcinoma cells. Materials and methods. SKOV-3 cells and primary epithelial ovarian carcinoma cells
were cultured in the presence of various concentrations of thalidomide. Cell proliferation was examined by MTT
proliferation assay. TNF-α and IL-6 levels were determined in the supernatants of the cell cultures by ELISA,
and MMP activity was examined by gelatin zymography. Results. Thalidomide did not significantly affect the
proliferation and growth of SKOV-3 cells. However, it decreased significantly the capacity of SKOV-3 cells and
primary epithelial ovarian carcinoma cells to secrete TNF-α. Thalidomide also significantly decreased the capacity
of SKOV-3 cells, but not primary epithelial ovarian carcinoma cells, to secrete MMP-9 and MMP-2. However,
thalidomide did not affect IL-6 secretion in SKOV-3 cells or primary epithelial ovarian carcinoma cells. Conclusion.
Our study suggests that thalidomide distinctly affected TNF-α, IL-6 and MMPs secretion by an ovarian carcinoma
cell line (SKOV-3) and primary ovarian cancer cells. This might suggest a different susceptibility of these two types
of cells to thalidomide, and/or that the mechanisms of secretion of the factors examined are differently regulated
in these cells. Our results may deepen our understanding the mechanism/s of action of thalidomide in ovarian
carcinoma cells. The results might have important implications in future therapeutic strategies that will incorporate
thalidomide and other cytokine inhibitors in the treatment of epithelial ovarian carcinoma.},
DOI = {10.1684/ecn.2013.0342}
}